Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
- PMID: 24457417
- DOI: 10.1038/nrc3670
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Abstract
In this Timeline, we describe the characteristics of tumour antigens that are recognized by spontaneous T cell responses in cancer patients and the paths that led to their identification. We explain on what genetic basis most, but not all, of these antigens are tumour specific: that is, present on tumour cells but not on normal cells. We also discuss how strategies that target these tumour-specific antigens can lead either to tumour-specific or to crossreactive T cell responses, which is an issue that has important safety implications in immunotherapy. These safety issues are even more of a concern for strategies targeting antigens that are not known to induce spontaneous T cell responses in patients.
Similar articles
-
Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?Mol Med Today. 1997 Jun;3(6):261-8. doi: 10.1016/S1357-4310(97)01049-6. Mol Med Today. 1997. PMID: 9211417 Review.
-
Prospects for adoptive T cell therapy.Curr Opin Immunol. 1997 Oct;9(5):702-8. doi: 10.1016/s0952-7915(97)80052-0. Curr Opin Immunol. 1997. PMID: 9368780 Review.
-
Targeting tumours with genetically enhanced T lymphocytes.Nat Rev Cancer. 2003 Jan;3(1):35-45. doi: 10.1038/nrc971. Nat Rev Cancer. 2003. PMID: 12509765 Review.
-
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.Cancer Cell. 2020 Oct 12;38(4):454-472. doi: 10.1016/j.ccell.2020.07.013. Epub 2020 Aug 20. Cancer Cell. 2020. PMID: 32822573 Free PMC article. Review.
-
Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy.Clin Cancer Res. 2006 Sep 1;12(17):5023-32. doi: 10.1158/1078-0432.CCR-05-2682. Clin Cancer Res. 2006. PMID: 16951217 Review.
Cited by
-
Transcriptome analysis of anaerobic glycolysis effects on Jurkat T cell proliferation.Cent Eur J Immunol. 2024;49(2):194-202. doi: 10.5114/ceji.2024.142116. Epub 2024 Aug 12. Cent Eur J Immunol. 2024. PMID: 39381560 Free PMC article.
-
Developing Vaccines in Pancreatic Adenocarcinoma: Trials and Tribulations.Curr Oncol. 2024 Aug 23;31(9):4855-4884. doi: 10.3390/curroncol31090361. Curr Oncol. 2024. PMID: 39329989 Free PMC article. Review.
-
T lymphocyte‑related immune response and immunotherapy in gastric cancer (Review).Oncol Lett. 2024 Sep 6;28(5):537. doi: 10.3892/ol.2024.14670. eCollection 2024 Nov. Oncol Lett. 2024. PMID: 39319215 Free PMC article. Review.
-
mRNA vaccines: a new era in vaccine development.Oncol Res. 2024 Sep 18;32(10):1543-1564. doi: 10.32604/or.2024.043987. eCollection 2024. Oncol Res. 2024. PMID: 39308511 Free PMC article. Review.
-
MDM2 inhibitors in cancer immunotherapy: Current status and perspective.Genes Dis. 2024 Mar 28;11(6):101279. doi: 10.1016/j.gendis.2024.101279. eCollection 2024 Nov. Genes Dis. 2024. PMID: 39263534 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources